IP Library Patent Application 14810005
Patent Application
App. No. 14/810,005

THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/810,005
Abstract

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.2 to about 20 weight percent of epothilone, e.g. epothilone B; and about 50 to about 99 weight percent biocompatible polymer.

Claims (23)

1 . A therapeutic nanoparticle comprising:

about 0.2 to about 20 weight percent of epothilone; and

about 50 to about 99.8 weight percent biocompatible polymer, wherein the biocompatible polymer is a diblock poly(lactic) acid-poly(ethylene)glycol copolymer, wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to about 90 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 12 kDa.

2 . The therapeutic nanoparticle of claim 1 , wherein said epothilone is epothilone B.

3 . The therapeutic nanoparticle of claim 2 , comprising about 0.2 to about 10 weight percent of epothilone.

4 . The therapeutic nanoparticle of claim 1 , comprising about 0.2 to about 5 weight percent of epothilone.

5 . The therapeutic nanoparticle of claim 1 , wherein the diameter of the therapeutic nanoparticle is about 60 nm to about 190 nm.

6 . The therapeutic nanoparticle of claim 1 , wherein the particle substantially immediately releases less than about 60% of the therapeutic agent after 2 hours when placed in a phosphate buffer solution at 37° C.

7 . The therapeutic nanoparticle of claim 1 , wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 16 kDa and poly(ethylene)glycol having a number average molecular weight of about 5 kDa.

8 . The therapeutic nanoparticle of claim 1 , further comprising about 0.2 to about 10 weight percent of a diblock poly(lactic)-poly(ethylene)glycol copolymer covalently bound to a targeting ligand.

9 . A plurality of therapeutic nanoparticles prepared by:

combining epothilone or pharmaceutically acceptable salts thereof and a diblock poly(lactic)acid-polyethylene glycol having a number average molecular weight of about 15 to about 90 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 12 kDa, with an organic solvent to form a first organic phase having about 10 to about 40% solids;

combining the first organic phase with a first aqueous solution to form a second phase;

emulsifying the second phase to form an emulsion phase;

quenching the emulsion phase to form a quenched phase;

adding a drug solubilizer to the quenched phase to form a solubilized phase of unencapsulated therapeutic agent; and

filtering the solubilized phase to recover the nanoparticles, thereby forming a slurry of therapeutic nanoparticles each having about 0.2 to about 20 weight percent of epothilone.

10 . The plurality of therapeutic nanoparticles of claim 9 , wherein the epothilone is epothilone B.

11 . A controlled release therapeutic nanoparticle comprising:

about 0.2 to about 20 weight percent of epothilone or a pharmaceutically acceptable salt thereof; and poly(lactic) acid-poly(ethylene)glycol copolymer or a poly(lactic)-co-poly (glycolic) acid-poly(ethylene)glycol copolymer, wherein said epothilone is released at a controlled release rate over a period of at least 1 day or more when administered to a patient; and wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to about 90 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 12 kDa.

12 . The controlled release therapeutic nanoparticle of claim 11 , wherein said epothilone is epothilone B.

13 . A pharmaceutical aqueous suspension comprising a plurality of nanoparticles of claim 1 , having a glass transition temperature between about 37° C. and about 50° C. in said suspension.

14 . The pharmaceutical aqueous suspension of claim 13 , wherein the glass transition temperature is between about 37° C. and about 39° C.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2016
From: BIND THERAPEUTICS, INC.
To: PFIZER INC.
Reel/Frame 040707/0868 →